New Drug Lepodisiran Shows Promise in Reducing Heart Disease Risk
A groundbreaking drug, Lepodisiran, developed by Eli Lilly, has shown remarkable results in reducing a genetically inherited risk factor for heart disease. According to a recent trial, the experimental drug cuts the levels of lipoprotein(a), or Lp(a), a stealthy cholesterol linked to heart attacks, by up to 94%.
The findings, published in multiple health and pharmaceutical news outlets, indicate that a single dose of Lepodisiran could significantly lower the risk of cardiovascular events. The drug targets Lp(a), a protein that is difficult to manage through traditional cholesterol-lowering medications.
Eli Lilly's study involved patients with high levels of Lp(a), a condition that significantly increases the risk of heart disease. The results have sparked hope in the medical community for a new approach to managing this genetic predisposition to heart disease, potentially offering a one-time treatment solution.